STAT News · Scour

STAT+: Oregon hospitals won’t outsource to national physician chain after all

statnews.com·1w

Trump administration’s drug strategy is at odds with recent actions on funding, policy

statnews.com·1w

Administration report on most favored nation drug pricing raises new details

statnews.com·1w

STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review

statnews.com·1w

STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’

statnews.com·1w

Why the FDA is authorizing fruit-flavored vapes

statnews.com·1w

STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease

statnews.com·1w

STAT+: When the path to good AI is littered with bad data

statnews.com·1w

STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price

statnews.com·1w

STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more

statnews.com·1w

HHS tackles ‘overmedication’

statnews.com·1w

Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care

statnews.com·1w

Opinion: Dr. Glaucomflecken wants to make a stink

statnews.com·1w

STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field

statnews.com·1w

Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?

statnews.com·1w

STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations

statnews.com·1w

STAT+: Did AI really beat doctors at diagnosis?

statnews.com·1w

STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing

statnews.com·1w

STAT+: A new attack on AMA’s billing codes

statnews.com·1w

STAT+: Are analysts too quick to gloss over Lilly’s liver case?

statnews.com·1w

Log in to enable infinite scrolling